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ABSTRACT 
Aim: To compare head-to-head the effects of dapagliflozin and liraglutide on bone strength and bone 
material properties in a pre-clinical model of diabetes-obesity.  
Materials and methods: Combined low-dose streptozotocin and high fat feeding were employed in 
mice to promote obesity, insulin resistance and hyperglycaemia. Mice were administered daily for 28 
days with saline vehicle, 1mg/kg dapagliflozin or 25 nmol/kg liraglutide. Bone strength was assessed by 
three-point bending and nanoindentation. Bone material properties were investigated by Fourier 
transform infrared microspectroscopy/imaging.  
Results: Although diabetic controls presented with dramatic reductions in mechanical strength, no 
deterioration of bone microarchitecture was apparent. At the tissue level, significant alterations in 
phosphate/amide ratio, carbonate/phosphate ratio, tissue water content, crystal size index, collagen 
maturity and collagen glycation were observed and linked to alteration of matrix biomechanics. 
Dapagliflozin and liraglutide failed to improve bone strength by 3-point bending or bone 
microarchitecture during the 28-day-treatment period. At bone formation site, dapagliflozin enhanced 
phosphate/amide ratio, mineral maturity, and reduced tissue water content, crystal size index and 
collagen glycation. Liraglutide had significant effects on phosphate/amide ratio, tissue water content, 
crystal size index, mature collagen crosslinks, collagen maturity and collagen glycation. At bone 
formation site, both drugs modulated matrix biomechanics.  
Conclusions: This study highlighted that these two molecules are effective in improving bone material 
properties and modulating matrix biomechanics at bone formation site. This study also highlighted that 
the resulting effects on bone material properties are not identical between dapagliflozin and liraglutide 








Type 2 diabetes mellitus (T2DM) affects approximately 425 million adults worldwide and 
projected figures for 2045 estimate a rise of up to 48% reaching 629 million adults [1]. T2DM is 
characterized by insulin and glucose intolerances that result in the development of chronic 
hyperglycaemia and hyperinsulinemia and is considered a risk factor for secondary osteoporosis [2]. In 
T2DM, the propensity for fracture is greater than would be predicted by bone mineral density alone 
suggesting possible alterations of bone microarchitecture or material properties [3]. Glucose-lowering 
agents that result in greater hypoglycaemic events and hence augment the risk of falls, may enhance 
fracture risk. Independent of hypoglycaemic events, antidiabetic agents may also influence skeletal 
physiology, as observed with thiazolidinediones that augment adipogenesis at the expense of 
osteoblastogenesis and osteocyte apoptosis [4].    
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 
(SGLT2) inhibitors are among the most recent class of drugs approved for the treatment of T2DM. Both 
classes of antidiabetic agents contribute to reductions in fasting and postprandial glycaemia, HbA1c, 
systolic blood pressure and weight loss [5]. Interestingly, in opposition to what is observed with other 
newer glucose-lowering agents such as dipeptidylpeptidase-4 inhibitors, recent studies have indicated 
that several GLP-1RAs, including liraglutide and SGLT2i are capable of reducing major cardiovascular 
events, making these agents even more therapeutically attractive [6].    
Intriguingly, a higher number of treatment-emergent bone fractures with canagliflozin and 
dapagliflozin have been reported in patients with T2DM [7, 8]. However, the reason for higher fracture 
risk with SGLT2i is unclear and the effects of these compounds on bone strength, bone material 
properties and matrix biomechanics have not been thoroughly investigated. We hypothesize that 
SGLT2i lower bone strength by altering bone microarchitecture and/or tissue material properties. The 
primary goal of the present study was to compare head-to-head the effects of the SGLT2i, dapagliflozin, 
and GLP-1RA, liraglutide, on bone strength, material properties and matrix biomechanics in an animal 
model of T2DM induced by joint administration of a high fat diet and streptozotocin (STZ).  
 
2. MATERIAL AND METHODS 
2.1 Animals 
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All procedures were conducted according to UK Home Office Regulations (UK Animals Scientific 
Procedures Act 1986) and approved by Ulster University Animal Welfare and Ethical Review Body. Male 
Swiss mice (Hsd: NIHS background, Envigo, Oxon, UK) at 8-10 weeks of age were housed individually 
in an air-conditioned room at 22 ± 2°C with a 12-hour light/dark cycle and provided with tap water ad 
libitum. A group of 8 mice had free access to standard rodent chow (6.2% fat, 18.6% protein, total energy 
13.0 kJ/g) and administered once daily with saline for the last 28 days (Lean+saline). Additionally, 
twenty-four mice had free access to a high fat diet (45% fat, 20% protein; total energy 26.15kJ/g; product 
code 824053; Special Diet Service, Witham, UK) ad libitum. Fourteen and seven days before 
commencing pharmacological interventions, these mice received 50 mg/kg i.p. streptozotocin (STZ) 
prepared in sodium citrate buffer (pH 4.5). Supplementary Figure 1 illustrates the design of the animal 
experiment. All animals exhibited fasting blood glucose concentration >13 mmol/L and were recruited 
into the study and considered diabetic. Diabetic mice were randomly allocated into three groups 
(n=8/group): Group 1 - Diabetic mice with saline vehicle (Diabetic+saline; 0.9% NaCl, i.p., once-daily); 
Group 2 – Diabetic mice with dapagliflozin (Diabetic+Dapaglifozin; 1 mg/kg, per os, once-daily); Group 
3 – Diabetic mice with liraglutide (Diabetic+Liraglutide; 25 nmol/kg, i.p., once-daily). Dosing of 1mg/kg 
dapagliflozin (p.o) and 25 nmol/kg liraglutide (i.p.) was based on previous literature [9, 10]. Saline, 
dapagliflozin and liraglutide were administered for 28 days, a period that was previously shown to 
induced significant improvement in tissue material properties [11]. Ten and three days before sacrifice, 
animals were administered with calcein (10 mg/kg; i.p.). Among all SGLT2 inhibitors, dapagliflozin was 
chosen as at the time of the study, it presented the highest SGLT2 inhibition selectivity. Through the 
course of this study, blood glucose level was assessed every week in non-fasted mice. At the end of the 
study, an oral load of glucose (18 mmol/kg) was administered to mice after an initial fast of ~12-h. Blood 
samples were collected from the tail vein as indicated below at 0-, 15-, 30-, 60- and 120-min post glucose 
administration. Insulin sensitivity test were also performed two days later by injecting intraperitoneally 
25U/kg bovine insulin to non-fasted mice. Blood glucose was measured as indicated below at 0-, 30- 
and 60-min post-insulin administration. At necropsy, femurs were cleaned of soft tissues and stored 
either in saline-soaked gauze at -20°C (bone strength assessment) or in 70% ethanol at 4°C (Fourier 
transform infrared microspectroscopy/imaging) until used.  
 
2.2. Biochemical analyses 
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Blood samples were collected from the tail vein of conscious mice into chilled fluoride/heparin 
microcentrifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged at 13,000g for 30 seconds 
(Beckman Instruments, Galway Ireland). Glucose concentrations were measured using Ascencia 
Contour Blood Glucose Meter (Bayer healthcare) and plasma insulin determined using modified 
dextran-coated charcoal RIA [12].  
2.3. Three-point bending 
Three-point bending experiments were performed on left femurs after rehydrating bones at 4°C for 24 h 
and letting them warm up to room temperature (22 ± 2°C) for at least 6 h. Femurs were loaded to failure 
at room temperature at 0.5 mm/min using an Instron 5942 (Instron, Elancourt, France). The lower span 
length was set to 8 mm. Femur length was measured with digital caliper using anatomical reference 
point (great trochanter, femoral condyle). The mean femur length was measured at 14 mm and did not 
vary between groups. The anterior surface was subjected to tension and the posterior surface to 
compression. Load and displacement were digitally recorded at a sampling rate of 100 Hz and measured 
using a 500 N load cell (Instron) with an accuracy down to 0.5 N (data supplied by Instron). The load-
displacement curve was recorded and plotted with the Bluehill 3 software (Instron). Whole-bone 
biomechanical parameters were deduced from load-displacement curve. After three-point bending, left 
femur was fixed in 10% formalin, analysed by microCT (see below) and tissue-level biomechanical 
parameters were calculated with beam theory equations.   
 
2.4. MicroCT and bone histomorphometry 
MicroCT analyses were performed after 3-point bending on left femurs with a Skyscan 1172 
microtomograph (Bruker MicroCT, Kontich, Belgium) operated at 70 kV, 100 µA, 340-ms integration 
time. The isotropic pixel size was fixed at 4 µm, the rotation step at 0.25° and exposure was done with 
a 0.5-mm aluminium filter. Each 3D reconstruction image dataset was binarized using global 
thresholding. Trabecular volume of interest (VOI) was located 0.5 mm above the distal growth plate and 
extended on 2-mm up to the diaphysis. Cortical volume of interest was positioned at the femur midshaft 
4 mm above the distal growth plate and extended on 0.5 mm in upward and downward directions. All 
microCT parameters were determined according to guidelines and nomenclature proposed by the 
American Society for Bone and Mineral Research [13].  After microCT scans, femurs were embedded 
undecalcified in polymethylmethacrylate at 4°C.  Coronal sections of the distal half (7-µm thickness) 
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were cut, stained with conventional bone staining (Goldner trichrome, toluidine blue, tartrate resistant 
acid phosphatase) and analysed by a trained bone pathologist blinded to the treatment group. 
Histomorphometrical parameters were assessed according to the guidelines provided by the American 
Society for Bone and Mineral Research [14].   
 
2.5. Fourier-transform infrared microspectroscopy and imaging 
Right femurs were embedded undecalcified in pMMA at 4°C. Cross-sectional sections (1 µm-thick) of 
femur diaphysis, located 6 mm above the end of the distal condyle, were cut with a Histo diamond knife 
(Diatome Ltd, Nidau, Switzerland) mounted on a Leica UC7 ultramicrotome (Leica Microsystems SAS, 
Nanterre, France). Sections were deposited onto barium fluoride optical windows.  
Fourier transform infrared microspectroscopy (FTIRM) was performed at bone formation site in cortical 
bone by recording infrared spectra only between double calcein labelling at periosteal and endosteal 
envelopes. Briefly, three spectra were recorded in both envelope per animal with a spectral resolution 
of 4cm-1 on the range 750-2000 cm-1. A Bruker Vertex 70 spectrometer (Bruker optics, Ettlingen, 
Germany) was interfaced with a Bruker Hyperion 3000 infrared microscope equipped with a single 
element mercury-cadmium-telluride (MCT) detector cooled with liquid nitrogen. Each spectrum was 
corrected for Mie scattering with the RMieS-EMSC_v5 algorithm (kind gift of Prof Peter Gardner, 
University of Manchester, UK).  Prior to being subjected to pMMA subtraction, the area of the 1715 - 
1745 cm-1 peak, corresponding to the C=O vibration of pMMA, and the amide I band, located between 
1590 - 1710 cm-1 were computed. After pMMA subtraction, spectra were vector normalized for the v1,v3 
phosphate band, located between 900-1200 cm-1, and second derivative spectroscopy was applied to 
find the position of underlying peaks. Curve fitting was performed with a routine script in Matlab (The 
MathWorks, Natick, USA) using second derivative minima as a loading vector for subpeak locations. 
Supplementary table 1 summarizes peak assignment. The evaluated infrared spectral parameters were:  
• Tissue water content, calculated as the area ratio of the pMMA peak (1715-1745 cm-1) to amide 
I (1590-1710 cm-1), both computed before pMMA subtraction, similar to nanoporosity 
computation from Raman spectra [15]. This approach takes advantage of the fact that water is 
replaced by pMMA during the embedding process, the computed ratio is used as a proxy for 
water content. In bone tissue, water generally exists within pores and bound to the matrix. 
Matrix‐bound water is not a monolayer but rather a series of coordinated water molecules, the 
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outermost of which may be removed by the tissue processing (dehydration through acetone, 
clearing with xylene and subsequent pMMA embedding). Thus, the tissue water content inferred 
in the present study may be loosely coordinated water, as well as water that was present in 
canaliculi in the studied voxel.;   
• Phosphate/amide ratio, calculated as the ratio of areas of the v1, v3 phosphate band at 900-
1200 cm-1 to the amide I band at 1585-1725 cm-1, both determined after pMMA subtraction; 
• Carbonate/phosphate ratio, calculated as the ratio of the v2 carbonate band at 850-900 cm-1 to 
the v1,v3 phosphate band;  
• mineral maturity calculated as the area ratio of the sub bands at ~1030 cm-1 and ~1110 cm-1 of 
the phosphate band;  
• crystal size index, that increases with increased crystallite size, was determined as the area 
ratio of sub bands located at ~1076 cm-1 and ~1058 cm-1 [16];  
• Collagen maturity determined as the area ratio of subbands peaking at ~1660 cm-1 (mature 
crosslinks) and ~1690 cm-1 (Immature crosslinks). The respective contribution of mature and 
immature crosslinks to total collagen crosslinks was computed to evaluate post-processing of 
collagen molecules as previously reported [17];  
• collagen glycation index was determined after demineralization of bone sections as the area 
ratio of the 1032 cm-1 subband to amide I as previously validated [18].   
No differences were evidenced between periosteal and endosteal envelopes and as such data 
presented hereafter corresponds to pooled data.  
Fourier transform infrared imaging (FTIRI) was performed in the posterior quadrant of femur midshaft. 
A focal plan array detector (64x64 pixels) was preferred to the single element MCT detector in the 
experimental setup described above. A spectral hypercube on the range 900-2000 cm-1 was recorded 
for each pixel with a spectral resolution of 8 cm-1. The corresponding infrared image represented an 
area of 540 um x 540 um with a ~5-11 um spatial resolution. Each spectrum was corrected for Mie 
scattering with the RMieS-EMSC_v5 algorithm.  Prior to pMMA subtraction, the area of the 1715 - 1745 
cm-1 peak, corresponding to the C=O vibration of pMMA, and the amide I band, located between 1590 
- 1710 cm-1 were computed. After pMMA subtraction, spectra were vector normalized for the v1,v3 
phosphate band, located between 900-1200 cm-1. The evaluated parameters were:  
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• Tissue water content, calculated as the intensity ratio of the pMMA peak (~1730 cm-1) to amide 
I (~1656 cm-1), both computed before pMMA subtraction.   
• Phosphate/amide ratio, calculated as the ratio of areas of the v1, v3 phosphate band to the 
amide I band; 
• Carbonate/phosphate ratio (intensity v3 carbonate located at ~1415 cm−1/1030 cm−1) was 
computed after subtracting the organic matrix spectrum [19]. 
• Mineral maturity calculated as the intensity ratio at 1030 cm-1 and 1110 cm-1;  
• Crystal size index as the intensity ratio at 1076 cm-1 and 1058 cm-1;  
• Collagen maturity determined as the intensity ratio at ~1660 cm-1 (mature crosslinks) and ~1690 
cm-1 (Immature crosslinks).  
• Collagen glycation index determined as the area ratio of the ~1032 cm-1 subband to amide I.   
Histogram distribution for each compositional parameter was plotted and the mean and full width at half 
maximum of the pixel distribution (excluding non-bone pixels) were computed and represented as mean 




Measurement of matrix biomechanics was performed by nanoindentation. This technique acquires 
force-displacement data of a pyramidal diamond indenter that is pressed onto a material sample. In 
opposition to three-point bending, nanoindentation is independent of bone geometry and 
microarchitecture. After cutting sections for FTIRI/FTIRM, pMMA blocks were polished to a 1-µm finish 
with diamond particles (Struers, France). After polishing, the sample surface was estimated at 10 um 
from sections observed by FTIRI/FTIRM. The polished surface was examined with a confocal Leica SP8 
microscope (Leica Microsystems, Nanterre, France) set at 488 nm for excitation and 515-580 nm for 
emission for the presence of double calcein labelling. Blocks were then subjected to rehydration in saline 
24h prior to nanoindentation testing at room temperature. Nanoindentation was performed with the 
NHT2-TTX system (Anton Paar, Les Ulis, France). Briefly, this system is composed of an epi-illumination 
microscope that allows precise examination of sample surface and marking of indentation location, a 
motorized stage, that allows translation of the sample from the epi-illumination microscope to the 
nanoindentation probe. Indentation were made between double calcein labelling with a depth of 900 
nm.  At maximum load, a holding period of 15 seconds was applied to avoid creeping of the bone 
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material. The following material properties at the matrix-level, maximum load, indentation modulus, 
hardness and work of indentation, were determined according to Oliver and Pharr [20]. 
 
2.7. Statistical analysis 
All data were analysed using Prism 6.0 (GraphPad Software Inc., La Jolla, CA). Equal variance between 
groups were tested with the Brown-Forsythe test. One-way ANOVA and Tukey’s multiple comparison 
tests, with a single pooled variance, were employed to test for significance in any of the studied 




3.1. Short-term treatment of dapagliflozin or liraglutide reduced fasted blood glucose level and 
insulin resistance 
As expected, saline-treated diabetic mice presented with high blood glucose levels through the full 
course of this study (Figure 1A). Administration of dapagliflozin or liraglutide, significantly reduced blood 
glucose levels from the 8th day of treatment onwards (Figure 1A). Oral glucose tolerance test revealed 
that saline-treated diabetic animals exhibited higher AUC glucose and AUC plasma insulin (Figure 1B-
C). Twenty-eight-day treatment with dapagliflozin or liraglutide significantly reduced glucose excursion 
during the oral glucose tolerance test and a lower insulin response suggesting improvements in glucose 
metabolism. Similarly, treatment with dapagliflozin or liraglutide led to significant improvements in insulin 
sensitivity compared to saline-treated diabetic animals (Figure 1D).  
 
3.2. Short-term treatment with dapagliflozin or liraglutide did not restore significantly bone 
strength in diabetic animals 
We examined effects of diabetes and pharmacological interventions with dapagliflozin or liraglutide on 
bone strength at the femur midshaft (Table 1). Interestingly, at the whole-bone level, compared to lean 
animals, diabetic+saline mice presented with significant reductions in ultimate displacement (40%, 
p=0.023), post-yield displacement (57%, p=0.012), post-yield work (43%, p=0.027) and work to fracture 
(34%, p=0.037). None of the other biomechanical parameters were significantly altered in saline-treated 
animals. Despite trends in enhancing ultimate displacement, post-yield displacement, post-yield work 
and work to fracture, none of dapagliflozin or liraglutide significantly ameliorated these parameters. At 
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the tissue level, ultimate strain (39%, p=0.039) and post-yield strain (56%, p=0.021) were significantly 
lower in saline-treated animals as compared with lean+saline mice. Here again, dapagliflozin and 
liraglutide, although despite slight enhancement, did not significantly improved these parameters.  
 
3.3. Type 2 diabetes mellitus or short-term treatment with dapagliflozin or liraglutide did not 
significantly alter bone microarchitecture 
In order to understand if changes in bone microarchitecture could account for the observed modifications 
of bone strength at the whole-bone levels, we investigated trabecular and cortical bone structure in 
femurs by microCT. Interestingly, cortical and trabecular bone microarchitectures were not different in 
diabetic+saline animals compared to lean controls (Figures 2A-B). Dapagliflozin- and liraglutide-treated 
mice presented with similar cortical and trabecular bone microarchitectures as diabetic+saline or 
lean+saline animals (Figures 2A-B).  
Furthermore, as SGLT2 inhibitors have been suspected to induce secondary hyperparathyroidism, we 
quantified osteoid surfaces and thickness by conventional histology. However, none of these two 
parameters were altered by diabetes or pharmacological intervention. Although freezing is not usually 
recommended for preserving morphological features of bone cells, the number of osteoclasts and 
osteoblasts have been quantified in TRAP-stained or toluidine blue-stained sections. Supplementary 
Figure 2 provides representative image of stained sections. Numbers of osteoblasts and osteoclasts 
were not significantly different between the four groups of animals (Figure 2B). No differences in the 
mineral apposition rate, mineralizing surface and bone formation rate were observed between the four 
groups of animals.    
 
3.4. Dapagliflozin and liraglutide ameliorated bone tissue material properties and bone matrix 
strength at bone formation site 
In order to determine the contribution of bone matrix composition in bone strength, we investigated 
several bone parameters over the full cortical width by Fourier transform infrared imaging (Figure 3A-
B). As compared with lean+saline animals, diabetic+saline mice presented with significant lower mean 
phosphate/amide (10%, p=0.037) and collagen maturity (10%, p<0.001), and higher mean tissue water 
content (38%, p=0.002), crystal size index (21%, p=0.010) and collagen glycation (86%, p=0.028). 
Distribution heterogeneity in all investigated parameters were similar between all groups of animals 
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(Supplementary Figure 3). Interestingly, the normalized collagen crosslinks distribution highlighted a 
significant reduction in immature and an increase in mature collagen crosslinks, suggesting faster 
maturation of the former. None of the two pharmacological interventions significantly changed these 
bone parameters despite trends of improvement.  
However, with respect to the bone formation rate observed in the present study, we could estimate that 
only ≈ 5% of the cortical width has been formed during the use of dapagliflozin or liraglutide (28-day 
treatment). With this in mind, we decided to investigate bone matrix composition at bone formation site 
to decipher the effects of SGLT2i and GLP-1RA on bone material properties.  
Supplementary Figure 4A presents mean Fourier infrared spectra for the four groups of animals at bone 
formation site. A broadening at 1100-1150 cm-1 was observed in diabetic+saline animals. This spectral 
region is representative of phosphate in poorly mature mineral (Supplementary Table 1). Diabetic+saline 
mice presented with significant lower phosphate/amide (19%, p<0.001) and carbonate/phosphate ratio 
(14%, p<0.001) and with higher tissue water content (96%, p<0.001) (Figure 3C). Interestingly, 
dapagliflozin and liraglutide significantly increased the phosphate/amide ratio to similar extent. However, 
despite both molecules decreased tissue water content (Figure 3C), the extent of this reduction was 
greater with dapagliflozin (64% vs. 43%, p=0.011).  
We next performed second derivative and curve fitting of the v1,v3 phosphate band (Supplementary 
Figure 4B). Surprisingly, the 1020 cm-1 subpeaks, corresponding to phosphate vibration in non-
stoichiometric apatite, and routinely used for the computation of mineral crystallinity, was not evidenced 
in diabetic animals albeit of their treatment. However, the 1030 cm-1 subpeak, indicative of phosphate 
vibration in apatitic environment and the 1110 cm-1 subpeak, indicative of phosphate vibration in non-
stoichiometric apatite, were clearly evidenced. We then chose the validated 1030/1110 cm-1 ratio as a 
measure of mineral maturity. Mineral maturity ratio was decreased without reaching statistical 
significance (p=0.085) in diabetic+saline animals (Figure 3C). However, crystal size index, that 
augments with crystal size in the 002, 211, 200 and 202 directions [16], was significantly elevated by 
41% in saline-treated diabetic animals (p=0.001). Interestingly, dapagliflozin administration resulted in 
significant higher mineral maturity ratio (60%, p=0.007) and lower crystal size index (35%, p<0.001). On 
the other hand, liraglutide administration resulted in only significant lower crystal size index (41%, 
p<0.001).  
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In order to investigate change in the organic phase of the bone matrix, we also computed the second 
derivative curve of the amide I-II bands followed by curve fitting (Supplementary Figure 4C). Saline-
treated diabetic mice presented with significant lower amount of mature collagen crosslinks (64%, 
p<0.001) and collagen maturity (52%, p<0.001), and higher collagen glycation (454%, p<0.001) (Figure 
3D). Administration of dapagliflozin resulted in significant higher mature and immature collagen 
crosslinks (38%, p=0.002 and 38%, p=0.010, respectively) and lower collagen glycation (55%, p<0.001) 
as compared with saline-treated diabetic mice. Administration of liraglutide led to significant higher 
mature collagen crosslinks (138%, p<0.001) and collagen maturity (107%, p<0.001) and lower collagen 
glycation (56%, p<0.001). We also computed the normalized amount of immature and mature collagen 
crosslinks (Figure 3D). Saline-treated diabetic animals presented with higher immature and lower 
mature normalized collagen crosslinks (p<0.001 and p<0.001, respectively), suggesting a reduction in 
post-processing of collagen molecules. Interestingly, liraglutide, but not dapagliflozin, was capable of 
restoring a normal post-processing of collagen molecules.   
 
3.5. Dapagliflozin and liraglutide ameliorated matrix biomechanics at bone formation site 
Biomechanical properties of the newly formed bone matrix were investigated by nanoindentation 
between double calcein labelling (Table 2). Diabetic+saline animals exhibited significant reductions in 
hardness (40%, p<0.001), indentation modulus (34%, p<0.001), maximum load (35%, p<0.001) and 
work of indentation (34%, p<0.001). Dapagliflozin administration led to significant higher values of 
hardness (49%, p=0.001), indentation modulus (31%, p<0.001), maximum load (43%, p<0.001) and 
work of indentation (52%, p<0.001). Administration of liraglutide had similar effects with higher hardness 
(39%, p=0.002), indentation modulus (18%, p=0.015), maximum load (29%, p<0.001) and work of 
indentation (28%, p=0.003). However, it is worth noting that the extent of augmentation in the work of 
indentation was significantly greater with dapagliflozin as compared with liraglutide (p=0.008).  
 
4. DISCUSSION 
Type 2 diabetes mellitus (T2DM) is associated with higher risk of fracture that is greater than would be 
predicted by bone mineral density, suggesting alterations of bone quality. Among all the parameters that 
account for bone quality, bone material properties represent the first hierarchical organization of bone 
that in essence is independent of macro- and microstructure. In the present study, we clearly 
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demonstrated that newly formed bone presented with a lower bone strength at the material level in 
diabetic animals as compared with lean animals. Reduction in bone strength were linked to modifications 
in bone material properties (tissue water content, phosphate/amide ratio, crystal size index, collagen 
maturity and collagen glycation) independently of effects on bone remodelling or bone microarchitecture. 
It is worth noting that although a short treatment period could be perceived as a weakness, it was chosen 
as (1), in previous animal models of type 2 diabetes, 28 days of administration was enough to exhibit 
changes at the bone material properties and (2) we wanted to evidence whether these changes occurred 
before changes in bone remodelling or bone microstructure were evident.  
 
The bone matrix is made of (1) an organic layer (~35 to 45% by volume), composed mainly by fibrillar 
type I collagen with enzymatic and non-enzymatic crosslinks, (2) a mineral phase (~35 to 45% by 
volume), composed of calcium phosphate in the form of poorly crystalline hydroxyapatite with carbonate 
and various vacancies and (3) water (~15 to 25% by volume) [21]. In the matrix, water exists in two 
states, free water, found in intracortical porosity, including the lacuno-canalicular network and voids 
between microfibrils, and bound water associated to hydrophilic residue of type I collagen and 
proteoglycan in the organic phase as well as crystal surface where it orients apatite crystals during 
biomineralization. Tissue water content decreases with the mineralization process when apatite crystals 
fill voids between type I collagen fibrils [22]. Vibrational determination of tissue water content takes 
advantage of water replacement during chemical dehydration and pMMA impregnation during the 
embedding process. Subsequently, tissue water content corresponds to free water, but also loosely 
bound water molecules. To the best of our knowledge, vibrational determination of tissue water content, 
as used in the present study, has never been compared head-to-head with UTE-MRI or 
thermogravimetric techniques. However, it is worth noting that bound water volume fraction, measured 
by UTE-MRI, was shown inversely correlated with tissue mineral density and ageing in rodents and 
humans [23, 24]. Similar observations have previously been observed with vibrational determination of 
tissue water content [15, 25]. 
In the present study, we evidenced that diabetes led to alterations of the three main components of the 
bone matrix that ultimately led to changes in mechanical behaviour at the material scale. The reason for 
higher tissue water content in diabetic bone matrix is unknown at the present. In intervertebral disks, the 
amount of advanced glycation end-products have been inversely correlated to the tissue water content 
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[26]. However, whether a similar correlation exists for bone remains to be investigated. In the present 
study, higher collagen glycation was observed in the presence of higher tissue water content. Lower 
phosphate/amide ratio, in addition to higher tissue water content, suggest that accumulation of apatite 
crystals is lower in diabetes and that the propensity of voids in the bone matrix is higher. This is in 
agreement with the reduction in hardness and indentation modulus measured by nanoindentation. With 
respect to the role of water in controlling apatite orientation and growth during biomineralization, it is not 
surprising to evidence changes in crystal size (bigger crystal as evidenced by higher crystal size index) 
suggesting of possible phase and compositional modifications. Alterations of crystal size have 
previously been associated with bone fragility [27]. Diabetes led also to abnormal collagen post-
processing with lower maturation of immature divalent collagen crosslinks to mature trivalent crosslinks. 
Interestingly dapagliflozin and liraglutide restored mineral parameters, and hence accumulation of 
apatite crystals into the bone matrix, in levels comparable to non-diabetic animals. However, only 
liraglutide, restored normal post-processing of type I collagen molecule suggesting that action outside 
of glycemic controls, are important for normal collagen physiology.   
 
Our present study, with a short duration of diabetes induction and treatment, highlighted that 
compromised bone strength is a rapid process in type 2 diabetes mellitus and primarily due to rapid 
alterations of bone material properties independently of changes in bone remodelling or bone 
microarchitecture. Bone cell fate and activities are regulated by several extracellular signals including 
matrix biomechanics. Matrix stiffness is an important modulator of bone cell activities with low matrix 
stiffness reducing osteoblast differentiation and bone formation [28]. Indeed, mesenchymal stem cells 
and osteoblasts, through membrane-expressed integrins, Piezo1/2 excitatory ion channels and 
cytoskeleton-associated protein sense changes in matrix stiffness and adapt their transcriptional activity 
by nuclear translocation of transcriptional coactivator with PDZ-binding motif (TAZ) and its paralog Yes 
associated protein (YAP) as well as MAPK and Wnt activation [29-32].  In the bone-diabetes field, it is 
well accepted that chronic hyperglycaemia, through the formation of advanced glycation end-products, 
reduce osteoblast and osteoclast activities [33-35]. However, in light with the important emerging role 
of matrix stiffness on cell activity, the undisputed effects of diabetes on bone material properties and 
hence matrix biomechanics and the kinetic of material properties alterations, changes in bone material 
properties not only contribute to reduced bone toughness, but also might be a signal triggering lower 
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bone cell activity in long-term uncontrolled diabetes. Figure 4 proposes a schematic of the perturbations 
leading to reduced bone strength in diabetes. Further studies are required to ascertain the role of local 
matrix stiffness changes on bone cell differentiation and function in diabetes.  
 
Despite trends, dapagliflozin and liraglutide failed to significantly improved bone strength at the whole-
bone levels. This was further confirmed by the lack of significant effects, again despite trends, on bone 
material properties when analyses were performed on the full cortical width. This is probably due to the 
low amount of cortical bone formed during pharmacological intervention. Indeed, based on bone 
formation rate evidenced in the present study, we estimated the amount of cortical bone build during the 
study at ~5%. However, when analyses were performed only at bone formation site, modulation of 
several bone material properties were evident with both molecules as well as modulation of matrix 
biomechanics. This is interesting and suggest that dapagliflozin and liraglutide do not modify the 
characteristic of bone formed before treatment. However, it would be interesting to assess whether the 
improvement in bone material properties observed with dapagliflozin and liraglutide persist when the 
bone matrix maturates. No effects of both dapagliflozin and liraglutide have been evidenced on either 
bone formation rate or osteoid parameter. However, it is worth noting that although not significant, 
osteoid surface and thickness had a trend to higher values in dapagliflozin- or liraglutide-treated animals 
and could also support the role of ameliorated matrix biomechanics and reduced advanced glycation 
end-products on bone formation.  
 
Although beneficial effects of liraglutide could have been envisaged based on previous published 
literature with GLP-1RAs [11, 36-38], the positive effects of dapagliflozin on bone, or more generally 
SGLT2i, were still the subject of some discussion. Long term studies of patients with T2DM and 
moderate impairment and/or prior risk/history of cardiovascular diseases reported a small but significant 
increase in treatment-emergent bone fractures with dapagliflozin and canagliflozin [7, 8]. Conflicting 
biomarker data suggests that canagliflozin increases bone turnover and reduces bone mineral density 
at the total hip [39], whereas dapagliflozin does not seem to affect any of these parameters [40]. One 
possible explanation for the discrepancy may reside in the dose that led to maximum inhibition of 
endogenous SGLT2 as the approved 10 mg dose of dapagliflozin results in approximately 65% inhibition 
while 300 mg dose of canagliflozin leads to full inhibition [41, 42]. To follow this idea, in the present study 
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we used a dose of 1mg/kg/day equivalent to a dose of ~100 mg/day for adult T2DM patients. However, 
we failed to demonstrate any detrimental effects of dapagliflozin on bone health and on the contrary we 
evidenced improvement in bone composition parameters at bone formation site.  
 
Several hypotheses had previously been formulated to explain the higher rate of fractures observed with 
SGLT2i, covering the spectrum of maintenance of sodium homeostasis to secondary 
hyperparathyroidism. We previously reported that in response to SGLT2i, compensatory mechanisms 
are observed in the primary convoluted tubule and represented by higher expression of other Na 
transporters, namely NaPi-2a and NHE3 [43].  Recently, Blau and colleagues proposed that SGLT2i 
therapy results in higher levels of serum phosphorus and plasma FGF-23 and lower concentrations of 
1,25-dihydrovitamin D [44]. These changes are thought to trigger secondary hyperparathyroidism. 
However, it is worth noting that when hyperparathyroidism is concomitant with vitamin D deficiency, as 
proposed by Blau and colleagues, the pattern of histomorphometrical features might be altered 
dramatically ranging from high to low bone turnover. However, although we did not measure plasma 
PTH as we did not withdraw enough blood for such evaluation, in response to dapagliflozin, we did not 
evidence any modifications of bone microarchitecture or histomorphometrical features (osteoid 
parameter, number of osteoblasts or osteoclasts, bone formation rate) usually observed in cases of 
hyperparathyroidism. Furthermore, dapagliflozin-treated animals exhibited the same panel of 
histomorphometrical features as noted with liraglutide treatment. In light of the lack of data on 
hyperparathyroidism and vitamin D deficiency in previous studies with liraglutide, it is unlikely that this 
mechanism occurred in our study. Strengthening this view is the lack of significant increase in PTH and 
FGF-23 concentrations in canagliflozin-treated diabetic mice that has been reported previously [45].  
 
Thrailkill and colleagues, and in opposition to what we observed in the present study, reported previously 
ameliorations of bone biomechanics, including higher post-yield displacement and work-to-fracture, with 
canagliflozin in streptozotocin-injected diabetic DBA/2J mice [46]. These positive changes were linked 
to changes in bone microarchitecture, but it is worth noting that bone material properties have not been 
investigated by Thrailkill et al. This might appear controversial with our study, but it is worth noting that: 
(1) canagliflozin was administered for 10 weeks whereas dapagliflozin was only given for 4 weeks in our 
study; and (2) the STZ-DBA/2J mouse model is a type 1 diabetic model with compromised insulin 
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secretion rather than a type 2 diabetic mouse model as proposed for STZ-high fat fed mice. Supporting 
our data, Suzuki and colleagues were also unable to observe changes in bone mass following 9 weeks 
of Tofogliflozin, another SGLT2 inhibitor, in type 2 diabetic male KKAy rats [47]. Whether changes in 
bone microarchitecture observed in Thraikill et al. is due exclusively to canagliflozin will need further 
investigations in the future. In agreement with our study, recent meta-analyses of randomized clinical 
trials, population-based open cohort and national register-based studies failed to evidence any negative 
effects of SGLT2i on bone health in the diabetic population [48-50].  
 
In a previous head-to-head comparison between dapagliflozin and liraglutide, we demonstrated that 
both molecules led to similar extent in amelioration of blood glucose level (fasted and non-fasted), 
HbA1c and HOMA-IR [51]. This is interesting with respect to the different modes of action of these 
molecules. Dapagliflozin enhances urinary glucose excretion by inhibiting the function of the renal 
sodium-glucose contransporter-2 in the early proximal convoluted tubule. Although actions of 
dapagliflozin appear to be independent of insulin secretion, it improves insulin sensitivity, most likely as 
a result of sustained reduction in hyperglycaemia, alleviation of glucose toxicity and weight reduction 
through enhanced caloric loss [9, 52, 53]. On the other hand, liraglutide does not act on urinary glucose 
excretion but rather exhibits a range of beneficial actions represented by weight loss, induction of satiety, 
inhibition of gastric emptying, stimulation of insulin secretion and inhibition of alpha cell function [54]. 
Previously, we demonstrated that the most beneficial actions of GLP-1 receptor agonists on bone were 
mediated through amelioration of blood glucose level [11, 37]. However, in the present study, despite 
similar effects on blood glucose level, several differences at the tissue level were evidenced between 
the two molecules suggesting that in addition to amelioration of blood glucose level, these two molecules 
exert other actions to modulate bone material properties. As SGLT2 or the classical GLP-1 receptor is 
not expressed in bone [46, 55], modulation of bone material properties is probably indirect and will need 
to be further deciphered in the future.   
 
In conclusion, the present study highlighted that dapagliflozin and liraglutide treatment were capable of 
reversing some of the detrimental effects of diabetes on bone material properties and matrix 
biomechanics at bone formation site.  This sheds new light on the choice of glucose-lowering agents in 
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diabetes in order to reduce the risk of bone fracture with high effects on metabolic parameters. Further 
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7. FIGURE LEGENDS 
Figure 1: Effects of once-daily dapagliflozin or liraglutide on metabolic parameters. (A) Blood 
glucose was measured over the 28-day period at the apex of the tail vein in conscious mice. Glucose 
area under the curve (AUC) are shown. (B) Glucose tolerance and (C) insulin response to glucose at 
the end of the study. Glucose and insulin concentrations were measured prior to and after oral 
administration of glucose (18 mmol/kg) in 12-h fasted mice. Glucose and insulin AUC values post 
injection are also shown. (D) Glucose response to insulin measured at the end of the study period. 
Glucose concentrations were measured prior to and after injection of insulin (25 U/kg; i.p.) in non-fasted 
mice. Glucose area above the curve (AAC) values post injection are also shown. Values are means ± 
SD for 8 mice/group. *: p<0.05 vs. diabetic+saline. 
Figure 2: Effects of once-daily dapagliflozin or liraglutide on bone microarchitecture. (A) Cortical 
bone microarchitecture and (B) trabecular bone microarchitecture by high-resolution X-ray tomography 
and bone histomorphometry. Tt.Ar: total tissue area, Ma.Ar: marrow area, Ct.Th: cortical thickness, 
Ct.Po: cortical porosity, BV/TV: trabecular bone volume, Tb.N: trabecular number, Tb.Th: trabecular 
thickness, Tb.Sp: trabecular spacing, OS/BS: osteoid surface, O.Th: osteoid thickness, N.Oc/B.Pm: 
number of osteoclasts and N.Ob/B.Pm: number of osteoblasts. Values are means ± SD for 8 mice. *: 
p<0.05 vs. diabetic+saline.  
Figure 3: Effects of once daily dapagliflozin and liraglutide on bone material properties over the 
full cortical width and at bone formation site. Bone material properties were investigated by Fourier 
transform infrared imaging (FTIRI) (A-B) in the posterior quadrant and by Fourier transform infrared 
microspectroscopy (FTIRM) (C-D) at site of bone formation. For each FTIRI parameter, only the mean 
distribution has been reported. Normalized enzymatic collagen crosslinks (XL) have been computed as 
the percentage of total crosslinks. Lean+saline (Black bars), diabetic+saline (white bars), 
diabetic+dapagliflozin (light grey bars) and diabetic+liraglutide (dark grey bars). Values are means ± SD 
for 8 mice. *: p<0.05 vs. diabetic+saline, $: p<0.05 vs. diabetic+dapagliflozin. 
Figure 4: Schematic of bone changes with type 2 diabetes mellitus and dapagliflozin or 
liraglutide administration. Alteration of glucose metabolism leads to a chronic hyperglycaemia state 
and the generation of advanced glycation end-products (AGE). AGE target bone cells activities that 
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ultimately, in the long-term, lead to alterations in bone mass, microarchitecture and bone material 
properties reducing bone strength. In the present study, parameters affected by dapagliflozin or 
liraglutide have been highlighted in italic. Short-term administration of both pharmacological 
interventions led to significant improvement of chronic hyperglycaemia, bone material properties and 




Table 1: Biomechanical assessment at the midshaft femur. Whole-bone mechanical properties have 
been deduced from load-displacement curves. Tissue-level mechanical properties have been calculated 
from beam theory equations. *: p<0.05 vs. diabetic+saline. Values are mean ± SD of 8 mice/group.  
 Lean Diabetic 
Treatment Saline Saline Dapagliflozin Liraglutide 
Whole-bone mechanical properties 
Ultimate load (N) 19.7 ± 3.3 21.1 ± 3.0 21.3 ± 2.8 21.8 ± 3.3 
Ultimate displacement (mm) 0.73 ± 0.24* 0.44 ± 0.09 0.59 ± 0.24 0.54 ± 0.22 
Stiffness (N/mm) 83.8 ± 12.9 89.1 ± 20.3 89.8 ± 15.6 99.5 ± 17.4 
Yield load (N) 14.7 ± 2.7 16.2 ± 2.2 15.6 ± 3.0 15.8 ± 4.1 
Yield displacement (mm) 0.17 ± 0.04 0.20 ± 0.05 0.17 ± 0.02 0.16 ± 0.03 
Post-yield displacement (mm) 0.56 ± 0.23* 0.24 ± 0.09 0.41 ± 0.23 0.38 ± 0.25 
Pre-yield work (N.mm)  1.4 ± 0.6 1.7 ± 0.5 1.4 ± 0.4 1.3 ± 0.5 
Post-yield work (N.mm) 7.6 ± 2.6* 4.3 ± 1.7 6.8 ± 2.5 6.5 ± 2.5 
Work to fracture (N.mm) 9.1 ± 2.6* 6.0 ± 1.5 8.3 ± 2.7 7.9 ± 2.1 
Tissue-level mechanical properties 
Ultimate stress (MPa) 155 ± 26 169 ± 24 148 ± 19 153 ± 26 
Ultimate strain 0.054 ± 0.018* 0.033 ± 0.007 0.048 ± 0.020 0.043 ± 0.018 
Elastic modulus (GPa) 8.9 ± 1.4 9.5 ± 2.2 7.6 ± 1.3 8.6 ± 1.5 
Yield stress (MPa) 116 ± 21 129 ± 18 109 ± 21 111 ± 29 
Yield strain 0.013 ± 0.003 0.015 ± 0.004 0.014 ± 0.002 0.013 ± 0.003 
Post-yield strain 0.041 ± 0.017* 0.018 ± 0.007 0.034 ± 0.019 0.031 ± 0.020 
 
Table 2: Biomechanical assessment at bone formation site. Matrix biomechanics were measured 
by nanoindentation between double calcein labelling. *: p<0.05 vs. diabetic+saline; $: p<0.05 vs. 
diabetic+dapagliflozin. Values are mean ± SD of 8 mice/group. 
 Lean Diabetic 
Treatment Saline Saline Dapagliflozin Liraglutide 
Hardness (MPa) 822 ± 46* 493 ± 72  736 ± 111* 683 ± 57* 
Indentation modulus (GPa) 15.8 ± 1.0* 10.5 ± 0.8 13.8 ± 1.1* 12.4 ± 0.9* 
Maximum load (mN) 13.9 ± 0.1* 9.0 ± 1.1 12.9 ± 0.9* 11.6 ± 1.2* 
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Supplementary Figure 1: Schematic representation of the animal experiment design.  
 
  
Supplementary Figure 2: High magnification representative images of TRAP and toluidine blue 





TRAP staining Toluidine blue staining
Supplementary Figure 3: Effects of once daily dapagliflozin and liraglutide on bone material 
properties over the full cortical width. Bone material properties were investigated by Fourier 
transform infrared imaging in the posterior quadrant. For each parameter, pixel distribution respective 
to bone area, mean and width have been reported. Normalized enzymatic collagen crosslinks (XL) have 
been computed as the percentage of total crosslinks. Lean+saline (Black lines and bars), diabetic+saline 
(dashed lines and white bars), diabetic+dapagliflozin (light grey lines and bars) and diabetic+liraglutide 
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Supplementary Figure 4: Effects of once daily dapagliflozin or liraglutide on bone material 
properties at bone formation site. Bone material properties were investigated at bone formation site 
by Fourier transform infrared microspectroscopy. (A) Normalized mean bone spectra acquired at bone 
formation site after pMMA subtraction. The standard error of the mean of each mean spectrum is shown 
by the shaded area. (B) Inverted second derivative in the v1,v3 phosphate band. The position of spectral 
features, identified as peak in the second derivative plot, have been added on the top of each spectra. 
The number and position of these spectral features have been used in the curve fitting routine to resolve 
underlying peaks in the v1,v3 phosphate band. (C) Inverted second derivative in the amide I and II bands 
with their respective spectral features. 
 
 
Supplementary Table 1: FTIR band assignment 1-8  
Position (cm-1) Assignment 
960 υ1 PO43- 
982 PO3 symmetric in brushite, PO43- in hydroxyapatite 
1014 PO43- in carbonated apatite 
1022 PO43- in non-stoichiometric apatite 
1032 PO43- in stoichiometric apatite, advanced glycation end products after 
demineralization 
1039 Type B carbonate apatite 
1058 PO43- in apatite 
1076 PO43- in apatite 
1091 PO43- in stoichiometric apatite 
1101  
1111 Poorly crystalline apatite 
1122 υ6’ and υ6’’ stretch PO3 in HPO42- ions 




1554 υ(COO-) Glu 
1568 β-sheet 
1577 υ(COO-) Asp 
1597 υ(C-C) Tyr-O- 
1606 υ(C-C) Tyr-OH 
1614 δ(C-H) Tyr-OH 
1629 β-sheet 
1635 Triple helix 
1662 α-helix, pyridinoline 
1680 β-sheet, deoxypyridinoline 
1692 β-turn, divalent collagen crosslinks 
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